Boehringer Ingelheim

AHA: Boehringer plans 2027 survodutide submission after CV win

Boehringer is gearing up to take survodutide to regulators next year after the obesity drug proved its cardiovascular credentials in its latest study.

James Waldron Nov 9, 2026 9:45am

Boehringer biopharmaceutical manufacturing facility in Shanghai

Boehringer bags $7.4B Sino deal for 6 preclinical TCEs, ADCs

Nov 4, 2026 9:08am

Boehringer, Microsoft explore digital twins for clinical trials

Oct 26, 2026 2:49pm

ESMO: Boehringer builds case for late-phase rival to Imdelltra

Oct 23, 2026 10:30am

Zealand slides as Boehringer-partnered obesity drug underwhelms

Oct 1, 2026 6:15am

Boehringer adds $250M to Variant pact via cardio expansion

Sep 23, 2026 8:55am